Member Info for Brighty1

Thoth2, beautifully articulated as always. Not long now until transformational news arrives regarding SDC1801, SDC1802 and SRRA737. Good luck all Sareum investors, Brighty

SNG is looking more and more attractive by the day and don't forget that Richard Marsden has been talking up the Phase 3 trial as "an opportunity for a significant UK scientific breakthrough". We know SNG001 works and saves lives. We just need the rest of the global scientific / pharma / Gov sectors to cotton on. Good luck, Brighty

That is a cracking piece of Sherlock Holmes detective work GTC. Thank you.

I predict BARC at 225p by the end of this year. 350p within 18 months. Good luck, Brighty

I totally agree re our CEO. She is THE problem. Just look at the huge success of her tenure at The Guardian (not). We need someone with vision to electrify our share price. Our previous Ceo Adam Crozier had a strategy that created shareholder value. What exactly has our current ceo achieved for shareholders at ITV since she arrived? I can't think of one positive. Good luck, Brighty

What's really exciting here is what was tucked away in the last set of results. i.e. that revenue growth year-on-year excluding any revenues in either year from the DHSC was up 138%. This highlights the very strong underlying performance of the business with or without DHSC orders. So, just imagine when orders start flowing in what that will do to our bottom line and consequently our share price. We've already hit 130p+ since the IPO. That is going to be dwarfed soon when this re-rates on the back of hard and fast numbers. Good luck, Brighty.

I would suggest that the Sareum silence is because the BOD now know that SDC1801 is a winning formula as big as Molnupiravir, Favipiravir, Budesonide, Dexamethasone & Remdesivir. i.e. it is worth billions. The July 1st RNS confirmed as much with the data showing that SDC1801 had a profile superior to dexamethasone and similar to baricitinib. It won’t be too much longer before our share price reflects this. Good luck, Brighty

Not long now before one of the big pharmaceutical companies tables a blockbuster takeover offer for SNG or a mouth watering licencing deal. This is yet another great article reinforcing why SNG is the real deal. We are up there with Molnupiravir, Favipiravir, Pfizer’s PF-07321332, Budesonide Inhaler, Dexamethasone & Remdesivir in the fight against Covid. Those that are talking down this stock are doing so at their own peril and are being disingenuous. This is a cracking business with huge potential. Our share price will reach all time highs soon enough. Good luck, Brighty

Yes, excellent coverage for ABDX in The Telegraph and Daily Mail over the weekend. Great news for ABDX shareholders. Once those orders start rolling in and are communicated to the stock market this is going to rocket. The ABDX share price was over 130p a few months ago and will be much higher than that in due course. Vaccinations are only part of the answer. The end game has always been about testing. Investors are now waking up to this. Good luck, Brighty

All the dots are joining up here ready for a big licencing or takeover deal. A reminder of the mega bucks paid in the pharma sector e.g. This week Hikma Pharmaceuticals agreed to acquire Custopharm for $375 million with a further $50 million in milestones. Kymab was sold earlier this year for $1.4 billion and Otezla was acquired for $13.4 billion in cash a couple of years ago. Every day we are getting nearer and nearer to the tipping point moment for N4P. Good luck, Brighty

Exactly right. This piece of GSK news is coming at a very opportune time for Sareum. We know GSK has some very big patents due to expire in the next decade. They've also got activist investor Elliot Management biting at their heels re the GSK R&D pipeline. It's also worth noting that GSK's senior vice president and head of research for R&D in the past was our NED Michael Owen. Tim also spent his early career with the company as did our scientific advisor Harry Finch who was GSK's director of chemistry for R&D. The SDC-1801 Covid trial has come at a perfect time for Sareum. I wouldn't be at all surprised to hear that GSK is one of the leading candidates to do a licencing deal with Sareum. Watch this space as they say. Good luck, Brighty

Encouraging news for ABDX today regarding the 3.5million manufacturing number per month stated by AVCT. Dyor but looking more and more positive here. This was over 120p a few months ago.We just need to see the orders flow in now and 120p will be surpassed. Good luck, Brighty.

Agreed and I'm really looking forward to the 1pm briefing today. Plus, don't forget that Richard Marsden has been talking up the Phase 3 trial as "an opportunity for a significant UK scientific breakthrough". If the data for P3 is as good as we believe it to be then it's a huge moment for Synairgen, its shareholders and for UK science. Not long to wait now. Good luck, Brighty

5 years ago this very week the announcement was made of the licensing deal with Sierra. Lets hope the wait is now over. We know that SRA737 can save lives (as well as transform our share price). Good luck, Brighty

I'm generalising Mafuta but in its totality the FT article is highlighting that things are progressing from the vaccine to other areas of expertise and it looks as though we are going to hear more encouraging news about non vaccine treatments for Covid shortly from UK scientists. I'm starting to think that Agile will indeed be part of this newsflow. If so, Sareum could be part of this next phase. Good luck, Brighty

Some very interesting comments potentially for Sareum shareholders in the FT from Steve Bates, chief executive of the UK’s BioIndustry Association and a former member of Britain’s vaccines task force.

The FT article says that Bates would be “unsurprised” to see at least one antiviral drug ready to be rolled out in the coming weeks, potentially under an “emergency use authorisation”, through which products yet to win full regulatory approval can be made available during a public health crisis.

Could this be SDC1801 via Agile? If so, we are on our way to Thoth2's £1 a share.

The rest of the FT article, summarised below, also said that “People may have to adjust their expectations of how transformative this category of medicines will be”..

Efficacy levels might be far lower than the public had come to expect from the vaccines, Bates warned. “Because of this problem of when you administer them, it’s almost impossible to get a really good result statistically. And if you get an antiviral that works at 40 per cent, I think that will be brilliant,” he said.
In April Boris Johnson, UK prime minister, established an antivirals task force, modelled on the country’s successful vaccines task force.

He pledged “to have at least two effective treatments this year, either in a tablet or capsule form” that could be taken at home following a positive test or exposure to someone with the virus. But as yet there has been no word from the task force and its leader, pharmaceutical industry veteran Eddie Gray, on whether that target will be met.

The UK health department said there were “a number of exciting opportunities in the pipeline” and promised to provide “further details in due course”.

Good luck, Brighty

It will be takeover or major licencing time when the P3 news is revealed if the results are as encouraging as they have been to date. With data from SNG already showing that "treatment is leading to a threefold likelihood of recovery" our share price could literally skyrocket. Good luck, Brighty

When SNG stated a few months ago that "Significant progress continues towards a treatment for COVID-19" and our CEO is on record as saying "We believe this trial presents an opportunity for a significant UK scientific breakthrough" you have to feel very very confident about your investment. Good luck, Brighty

Yes and don't forget that Richard Marsden has been talking up the Phase 3 trial as "an opportunity for a significant UK scientific breakthrough". Excitingly for SNG investors we already know that it works.

For any doubters, here is RM's full quote from the RNS: "We need treatments as well as vaccines to fight highly pathogenic viruses such as SARS-CoV-2. Development of treatments like ours will remain necessary in cases where vaccines are not effective, for those who do not get vaccinated, and in case the virus mutates to the point where vaccines become less effective. We believe this trial presents an opportunity for a significant UK scientific breakthrough and, if given the right support, our drug could rapidly assist with the global crisis."

Says it all as far as I'm concerned. If the data for P3 is as good as we believe it to be then it's a huge moment for Synairgen and its shareholders.

Good luck, Brighty

Exactly right. ABDX was over 130p a few months ago. Anything is possible. Investors (and the general public) are now waking up to the fact that vaccinations are only part of the answer. The end game is and will always be about testing. Great news for ABDX investors.
Good luck, Brighty